转移性前列腺癌手术去势与药物去势:全国队列的使用与总生存
该回顾性队列研究纳入美国国家癌症登记库2004至2016年新发转移性前列腺癌男性24,805例,评估手术去势使用趋势及与总生存的关联。结果显示仅5.4%接受手术去势,使用率从2004年8.5%降至2016年3.5%;中位随访30个月,手术与药物去势的总生存无差异(HR 1.02,95%CI 0.95-1.09,p=0.6)。
要点
- 手术去势使用率低且逐年下降,2004年8.5%降至2016年3.5%。
- 私人保险与较少手术去势相关,医疗补助或无保险与更多手术去势相关。
- 中位随访30个月,手术与药物去势的总生存无显著差异。
核心结论
- 在当代真实世界队列中,手术去势使用率低且持续下降,尽管其可能具有优势且与药物去势生存率相似。
研究设计与样本
- 回顾性队列研究,从美国国家癌症登记库采样24,805例新发转移性前列腺癌男性(2004至2016年)。
- 采用多变量逻辑回归评估社会人口学因素与手术去势的关联,多变量Cox回归评估去势类型与总生存的关联。
主要发现
- 总体5.4%的男性接受手术去势,比例从2004年8.5%降至2016年3.5%(每滞后一年OR 0.89,95%CI 0.87-0.91,p<0.001)。
- 与Medicare相比,私人保险与较少手术去势相关(OR 0.73,95%CI 0.61-0.87,p<0.001),医疗补助或无保险与更多手术去势相关(OR 1.68,95%CI 1.34-2.11,p<0.001;OR 2.12,95%CI 1.58-2.85,p<0.001)。
- 地区中位收入大于$63,000与较少手术去势相关(vs 收入小于$38,000 OR 0.61,95%CI 0.43-0.85,p=0.004)。
- 中位随访30个月,去势类型与生存差异无关(手术 vs 药物 HR 1.02,95%CI 0.95-1.09,p=0.6)。
临床怎么用
- 手术去势使用率低且下降,临床决策时可结合患者保险状况与医疗可及性个体化选择去势方式。
- 手术与药物去势总生存相似,对于医疗可及性有限的患者,手术去势可能是一种合理选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Surgical castration for metastatic prostate cancer is used less frequently than medical castration yet costs less, requires less followup and may be associated with fewer adverse effects. We evaluated temporal trends and factors associated with the use of surgical castration. MATERIALS AND METHODS: This retrospective cohort study sampled 24,805 men with newly diagnosed (de novo) metastatic prostate cancer from a national cancer registry in the United States (2004 to 2016). Multivariable logistic regression assessed the association between sociodemographic factors and surgery. Multivariable Cox regression evaluated the association between castration type and overall survival. RESULTS: Overall 5.4% of men underwent surgical castration. This figure decreased from 8.5% in 2004 to 3.5% in 2016 (per year later OR 0.89, 95% CI 0.87-0.91, p <0.001). Compared to Medicare, private insurance was associated with less surgery (OR 0.73, 95% CI 0.61-0.87, p <0.001) while Medicaid or no insurance was associated with more surgery (OR 1.68, 95% CI 1.34-2.11, p <0.001 and OR 2.12, 95% CI 1.58-2.85, p <0.001, respectively). Regional median income greater than $63,000 was associated with less surgery (vs income less than $38,000 OR 0.61, 95% CI 0.43-0.85, p=0.004). After a median followup of 30 months castration type was not associated with differences in survival (surgical vs medical HR 1.02, 95% CI 0.95-1.09, p=0.6). CONCLUSIONS: In a contemporary, real-world cohort surgical castration use is low and decreasing despite its potential advantages and similar survival rate compared to medical castration. Men with potentially limited health care access undergo more surgery, perhaps reflecting a provider bias toward the perceived benefit of permanent castration.
引用
- Weiner AB, Cohen JE, DeLancey JO, et al. Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. J Urol. 2020. PMID: 31746656. doi:10.1097/JU.0000000000000684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。